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ABSTRACT 
Risperidone is considered as an atypical antipsychotic. It is considered as an effective treatment 
of psychotic disorders in adults. However, our understanding of its usage among young 
individuals is limited. In this study, the objective was to identify the safety profile of Risperidone 
among young children. Methodology wise, the study was conducted among children of less than 
5 years old who were treating behavioral problems associated with various childhood disorders. 
The study was conducted in a hospital in Nairobi, Kenya. Common childhood disorders were 
diagnosed using the Diagnostic and Statistical Manual (DSM IV) and those associated with 
disruptive behavioral problems. We used Clinical Global Impression- Severity (CGI-S) and 
Improvement (CGI-I) scales for symptoms severity and improvement respectively. We took 
informed consents from parents of the children and initiated Risperidone. The total of 12 patients 
were included in the study consist of PDD (n=4), PDD plus ADHD (n=2), PDD plus ADHD plus 
Intellectual disability (n=2), Cerebral Palsy with Epilepsy (n=2) and Global developmental delay 
(n=2). Baseline and end point CGI scores were 5-6 and 1-2 respectively. Baseline investigations 
such as lipid profile, fasting blood sugar levels, Electro cardiogram (ECG) were recorded and 
compared before and after initiation of risperidone. Dose range of risperidone was 0.5-2mg per 
day. Common side effects were sedation and weight gain in a few patients only. No life-
threatening side effects were noted. Our conclusion is that risperidone is well tolerated even in 
children below 5 years of age over a period of 1 year with improvement in target symptoms.  
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INTRODUCTION 
Risperidone is a typical antipsychotic and its indications for usage among adults include acute 
case of mania in bipolar disorder, schizophrenia, persistent aggression, Alzheimer’s disease, and 
conduct disorder. Previously, Risperidone was used for adults only, however, now it is started 
to use for youngsters such as age group of 5 years to 16 years especially after the approval of 
US FDA [1].  So far,  it is found to be safe and effective among this age group. However, there 
is limited data available about administering it for youngsters less than 5 years of age.  
 
MATERIAL AND METHODS 
The study was based on a tertiary care hospital located in Nairobi, Kenya. The department of 
Psychiatry and Child neurology was the focus point of this study. All patients in this department 
were referred by outpatient department. We included those children who were diagnosed with 
Pervasive development disorder, ADHD, Intellectual disability, and Cerebral Palsy [2]. Common 
symptoms of these patients were out of control behavior, aggression, and irritability. We took 
informed consents from guardian/parents of these children whom we included in the study. 
Initially, we administered smaller dose and gradually increased its quantity. Side by side, we 
used Clinical Global Impression-severity (CGI-S) and improvement (CGI-I) [3] scales. We 
continued follows up for 4 weeks and continued assessed clinical improvement and side effects. 
For some cases, we continued follow up to 1 year. Other indicators including ECG, Lipid profile, 
fasting blood sugar, and base line weight were also monitored.  
 
RESULTS 
In this present study, there were total of 12 patients who were included in the study. Among 
these patients, 4 had pervasive developmental disorder; 2 had PDD plus attention deficit 
hyperactive disorder; 2 had PDD plus ADHD plus intellectual disability; 2 had Cerebral palsy 
with epilepsy; and 2 had Global developmental delay. Their baseline and end point CGI scores 
were 5-6 and 1-2 respectively. We started administering the risperidone dose from 0.25 to 0.5 
mg. we gradually increased the dose in case of minimal or non-responsive to the lower doses. 
We administered dose increment among 10 patients out of total of 12 patients. We observed no 
side effects among 4 patients, and 2 patients showed abnormal weight gain.  
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Table 1: Shows base line and final assessment of weight and Fasting blood sugar level along with 
demographic details 
 
Gender Age  
in 
Years 
Diagnosis 
Results 
Weight – 
Pre 
Treatment 
Weight- 
Post 
Treatment 
FBS 
baseline 
FBS 
after 1 
year 
Male 3 CP with 
Epilepsy 
10 12 88 90 
Male 5 CP with 
Epilepsy 
12 13 76 87 
Male 4 CP with 
Epilepsy 
13 14 69 76 
Male 4 CP with 
Epilepsy 
14 15 70 75 
Female 3 PDD with 
AHDD 
12 12 78 79 
Male 3 CP with 
Epilepsy 
12 12.50 89 82 
Male 4 PDD with 
ADHD 
13 14 97 90 
Male 5 CP with 
Epilepsy 
14 15 91 89 
Female 5 CP with 
Epilepsy 
15 14 78 80 
Male 5 PDD with 
AHDD 
15 15 70 89 
Male 4 PDD with 
AHDD 
13 14 83 76 
Male 3 CP with 
Epilepsy 
12 12 85 89 
 
 
 
No patient included in our study showed severe side effects such as extra pyramidal side effects 
(EPS). We conducted other measures such as Lipid profile and fasting blood sugar and found no 
significant increase in base line levels. ormal fasting blood sugar levels were < 100mg/dl and 
normal Total Cholesterol levels were <300 mg/dl and normal Triglyceride levels < 150 mg/dl.  
 
 
Table-2: Shows base line and final lipid profile, CGI scores along with drug side effects 
 
Lipid Profile 
Baseline 
Lipid Profile after 1 
Year 
Side 
Effects 
after 4 
Weeks 
Side 
Effects 
after 6 
Months 
Side 
Effects 
after 1 
Year 
CGI 
Score 
CGI 
Score 
after 1 
Year 
TC TG TC TG No 
Effects 
No 
Effects 
No 
Effects 
6 2 
115 67 145 65 Sedation Weight 
Gain 
No 
Effects 
6 2 
 International Medical Science Research Journal,  Ohabuneyi & Nwafor, pp. 73-78 Page 76 
 
123 69 154 61 No 
Effects 
No 
Effects 
No 
Effects 
6 2 
165 75 167 63 No 
Effects 
No 
Effects 
No 
Effects 
5 1 
134 63 167 67 No 
Effects 
No 
Effects 
No 
Effects 
5 1 
122 55 178 68 Sedation Weight 
Gain 
No 
Effects 
6 1 
116 60 162 54 Sedation No 
Effects 
No 
Effects 
5 2 
118 76 189 57 No 
Effects 
No 
Effects 
No 
Effects 
6 2 
123 71 152 51 No 
Effects 
No 
Effects 
No 
Effects 
6 1 
113 74 146 80 Sedation Weight 
Gain 
No 
Effects 
6 1 
121 70 148 78 No 
Effects 
No 
Effects 
No 
Effects 
5 2 
115 81 154 82 No 
Effects 
No 
Effects 
No 
Effects 
5 2 
126 72 151 84 No 
Effects 
No 
Effects 
No 
Effects 
6 1 
 
Discussion 
Behavioral problems can lead to the developmental disorders and is a major problem these days. 
Common examples of behavioral problem include self-injurious behavior, hyperactivity, 
aggression, and irritability which are often associated with Pervasive developmental disorders, 
mental retardation, and ADHDs [4]. It is estimated that such behavior prevail among 4 to 9% of 
all children [5, 6]. The problem is that these behavioral problems interfere with rehabilitative 
efforts and pose severe challenges to parents, relatives, and other stakeholders such as educators 
and society [7]. It is recommended that in situation where behavioral problems interfere with 
daily activities, parents/guardian should seek pharmacological intervention. Typical 
Antipsychotics like haloperidol are commonly utilized, however, there risk of unwanted extra 
pyramidal symptoms is quite high. Atypical antipsychotics score over typicals in these side 
effects. Risperidone is also a solution for treating behavioral symptoms among adults. Most 
studies about its results are conducted among adults, and there is no such data of administering it 
among children less than 5 years of age [8]. Common behavioral problems among children can 
also be treated using the Risperidone as reports shows that it can help in overcoming these 
behavioral problems [9]. Here, it is important to mention that besides the medicine, the 
psychosocial intervention should be given priority for treating children behavioral problems [10]. 
Psychopharmacological intervention is required if symptoms causes significant distress to 
parents and other related individuals [11]. Based on this study, we reported that Risperidone can 
be used to treat effectively the disruptive behavior among preschool children. Our findings are 
matching with other studies findings which also reports similar findings. For example, study 
showed that Risperidone can be used for treatment of aggressive behavior in preschool children 
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[12]. Common diagnosis for which Risperidone is used includes disruptive behavior disorder, 
ADHD, ID, and PDD [10]. In our study, we administered the Risperidone among children who 
were less than 5 years of age. We found that among these children, the common side effects of 
the Risperidone are weight gain and sedation. Overall, we found that Risperidone can be used to 
treat behavioral problems along with other psycho-social support to children.  
CONCLUSION 
On study findings basis, our conclusion is that Risperidone is well tolerated among children 
below 5 years of age. We observed in improvement in targeted symptoms as observed by us and 
parents. The improvement is also associated with reduced family burden and improved quality of 
life.  
Limitations 
The study limitations included small sample size and hence we suggest a larger study in future 
which can be placebo-controlled investigation or double blind in nature.   
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